Comparison of antiviral effect of camel lactoferrin peptide (CLF36) and new generation drugs against hepatitis C virus

Document Type : Research Paper

Authors

1 PhD Candidate, Department of Animal Science, Faculty of Agriculture, Ferdowsi University of Mashhad, Mashhad, Iran.

2 Corresponding author. Professor, Department of Animal Science, Faculty of Agriculture, Ferdowsi University of Mashhad, Mashhad, Iran

3 Dept. of Animal Science, Faculty of Agriculture, Ferdowsi University of Mashhad, Mashhad, Iran

Abstract

Objective
Hepatitis C infection is one of the most common chronic infectious diseases in the world and about 3-5 million people are infected with this infection annually. Unfortunately, despite recent advances, there are still widespread problems for the treatment of these people and many needs have not been met. As a result, there is an urgent need for more effective treatment strategies to treat this disease. One of these new therapeutic approaches is the use of recombinant proteins, which have no side effects for the patient and at the same time are cheap and available.
Materials and methods
To conduct this study, the three-dimensional structures of virus proteases (NS2, NS3, NS4A, NS5A and NS5B) and recombinant peptide CLF36, were obtained. The chemical structure of new generation drugs was also downloaded from PubChem. To evaluate the stability of the predicted structures and to ensure the accuracy of the third structure of proteins, molecular dynamics simulations were performed using GROMACS software version 2019 and in a duration of 10 nanoseconds. Then, to evaluate the antiviral properties of the peptide, molecular docking was performed for peptides and drugs under static conditions. To evaluate the stability of the complexes, based on the results obtained from molecular docking, complexes with negative values of free binding energy were selected to perform molecular dynamics simulations. Finally, the obtained results were evaluated under dynamic conditions in GROMACS software. The engineered peptides were then designed according to the results and the sequence of the best engineered peptides was sent for synthesis. After cloning and expression of the recombinant peptide in the yeast host, the IC50 level of the peptide on the Huh7.5 liver cell line was determined and the virus-infected cells were treated with the desired peptide. After extracting RNA from the cells, the virus loaded in the sample. Were measured.
Results
Among the results obtained from various dockings performed between virus proteases and recombinant peptides and commercial drugs, it was found that the peptide-binding strength (average -99.92) was much higher than other drugs (average -61.54). This indicates the high antiviral property of the recombinant peptide. The results of molecular dynamics showed that the values of rmsd and hydrogen bonds and binding energy for CLF36 peptide bound to virus proteases compared to other drugs indicate a stronger binding of this peptide. In addition, the engineered peptide showed stronger antiviral activity compared to the natural peptide (binding energy was 8 units stronger). Examination of the function of the peptide in vitro also showed that this peptide has a stronger antiviral effect compared to drugs in that it was able to completely prevent the virus from multiplying in cells.
Conclusions
The final results of this study indicated that recombinant peptide, has strong antiviral properties. However, to confirm these results, additional laboratory studies are needed.

Keywords

References

مهرداد قاسمی میمندی, محمدرضا محمدآبادی, علی اسمعیلی زاده کشکوئیه, مهدیه منتظری (1395). بررسی انتساب افراد به جمعیت‌هایی از شترهای شمال استان کرمان با استفاده از نشانگرهای ریزماهواره‎. فصلنامه علمی ژنتیک نوین 11 (3), 329-335‎.
قاسمی مهرداد، محمدآبادی محمدرضا، اسمعیلی زاده‎ علی (1394). تنوع ژنتیکی شترهای شمال استان کرمان با استفاده از نشانگرهای ریز ماهواره‎. مجله تحقیقات تولیدات دامی 4 (1), 35-45‎.
قاسمی میمندی مهرداد, محمدآبادی محمدرضا, منتظری مهدیه‎ (1395). ارزیابی ساختار ژنتیکی شتر با استفاده از روش‌های PCA  و خوشه بندی سلسله مراتبی‎. مجله بیوتکنولوژی کشاورزی 8 (3), 83-96‎.
محمدآبادی محمدرضا, قاسمی میمندی مهرداد, منتظری مهدیه‎ (1397) بررسی تنوع ژنتیکی شترهای بومی شمال استان کرمان با استفاده از آماره‌های. نشریه اصلاح و بهنژادی دام 1(2)، 13-1.
Reference
Abe Ki, Nozaki A, Tamura K et al. (2007) Tandem Repeats of Lactoferrin‐Derived Anti‐Hepatitis C Virus Peptide Enhance Antiviral Activity in Cultured Human Hepatocytes. Microbiol Immunol 51, 117-125.
 
Agarwal S, Mehrotra RJJC (2016) An overview of molecular docking. JSM chem 4, 1024-1028.
 
Azzam H, Goertz C, Fritts M et al. (2007) Natural products and chronic hepatitis C virus. Liver Int 27, 17-25.
 
Bolscher JG, Adão R, Nazmi K et al. (2009) Bactericidal activity of LFchimera is stronger and less sensitive to ionic strength than its constituent lactoferricin and lactoferrampin peptides. Biochimie 91, 123-132.
 
Carugo O, Pongor S (2001) A normalized root‐mean‐spuare distance for comparing protein three‐dimensional structures. Protein Sci 10, 1470-1473.
 
Chikalov I, Yao P, Moshkov M et al. (2011) Learning probabilistic models of hydrogen bond stability from molecular dynamics simulation trajectories. BMC bioinformatics 12, 1-6.
 
Chung BK-S, Lee D-Y (2012) Computational codon optimization of synthetic gene for protein expression. BMC Syst Biol 6, 1-14.
 
De Clercq E (2007) The design of drugs for HIV and HCV. Nat Rev Drug Discov 6, 1001-1018.
 
Dial EJ, Lichtenberger LM (2002) Effect of lactoferrin on Helicobacter felis induced gastritis. Biochem Cell Biol 80, 113-117.
 
El-Fakharany EM, Sánchez L, Al-Mehdar HA et al. (2013) Effectiveness of human, camel, bovine and sheep lactoferrin on the hepatitis C virus cellular infectivity: comparison study. Virol J 10, 1-10.
 
Ferenci P (2012) Treatment of chronic hepatitis C–are interferons really necessary? Liver Int 32, 108-112.
 
Ghasemi Meymandi M, Mohammadabadi MR, Esmailizadeh AK (2015) Genetic variation of camels in the North of Kerman province using microsatellite markers. Anim Product Res 4 (1), 35-45 (In Persian).
 
Ghasemi Meymandi M, Mohammadabadi MR, Esmailzade A, Montazeri M (2016a) Assigning Individuals to the Camel Populations of North of Kerman Province Using Microsatellite Markers. Modern Genet J 11 (3), 329-335 (In Persian).
 
Ghasemi Meymandi M, Mohammadabadi MR, Montazeri M (2016b) Analysing Genetic Structure of Camelus dromedarius Using PCA and Hierarchical clustering methods. Agri Biotec J 8 (3), 83-96 (In Persian).
 
Gifford JL, Hunter HN, Vogel H (2005) Lactoferricin. Cell mol life sci 62, 2588-2598.
 
Hadizadeh M, Mohammadabadi MR, Niazi A, et al. (2013) Use of bioinformatics tools to study exon 2 of GDF9 gene in Tali and Beetal goats. Modern Genet J 8 (334), 283-288 (In Persian).
 
Hadizadeh M, Niazi A, Mohammad Abadi M, et al. (2014) Bioinformatics analysis of the BMP15 exon 2 in Tali and Beetal goats. Modern Genet J 9(1), 117-120 (In Persian).
 
Haney EF, Nazmi K, Bolscher JG et al. (2012) Structural and biophysical characterization of an antimicrobial peptide chimera comprised of lactoferricin and lactoferrampin. Biochim Biophys Acta 1818, 762-775.
 
Harrington JM, Shannon HS (1976) Incidence of tuberculosis, hepatitis, brucellosis, and shigellosis in British medical laboratory workers. Br Med J 1, 759-762.
 
He F (2011) Bradford protein assay. Bio-Protocol e45-e45.
 
He Y-M, Ma B-G (2016) Abundance and temperature dependency of protein-protein interaction revealed by interface structure analysis and stability evolution. Sci Rep 6, 1-8.
 
Hu K, Zhu Z, Mathahs MM et al. (2020) Metalloprotoporphyrin Inhibition of HCV NS3-4A Protease: Structure–Activity Relationships. Drug Des Dev Ther 14, 757.
 
Ikeda M, Nozaki A, Sugiyama K et al. (2000) Characterization of antiviral activity of lactoferrin against hepatitis C virus infection in human cultured cells. Virus Res 66, 51-63.
 
Ikeda M, Sugiyama K, Tanaka T et al. (1998) Lactoferrin markedly inhibits hepatitis C virus infection in cultured human hepatocytes. Biochem Bioph Res Co 245, 549-553.
 
Inamullah I, Idrees M, Ahmed H et al. (2011) Hepatitis C virus genotypes circulating in district Swat of Khyber Pakhtoonkhaw, Pakistan. Virol J 8, 1-5.
 
Ishii K, Takamura N, Shinohara M et al. (2003) Long-term follow-up of chronic hepatitis C patients treated with oral lactoferrin for 12 months. Hepatol Res 25, 226-233.
 
Khan JA, Kumar P, Paramasivam M et al. (2001) Camel lactoferrin, a transferrin-cum-lactoferrin: crystal structure of camel apolactoferrin at 2.6 Å resolution and structural basis of its dual role. J Mol Biol 309, 751-761.
 
Kirkpatrick CH, Green I, Rich RR et al. (1971) Inhibition of growth of Candida albicans by iron-unsaturated lactoferrin: relation to host-defense mechanisms in chronic mucocutaneous candidiasis. J Infect Dis 124, 539-544.
 
Konishi M, Iwasa M, Araki J et al. (2006) Increased lipid peroxidation in patients with non‐alcoholic fatty liver disease and chronic hepatitis C as measured by the plasma level of 8‐isoprostane. J Gastroen Hepatol 21, 1821-1825.
 
Krieger E, Nabuurs SB, Vriend G (2003) Homology modeling. Method Biochem Anal 44, 509-524.
 
Kwo PY, Badshah MB (2015) New hepatitis C virus therapies: drug classes and metabolism, drug interactions relevant in the transplant settings, drug options in decompensated cirrhosis, and drug options in end-stage renal disease. Curr Opin Organ Tran 20, 235-241.
 
Lee J-K, Park S-C, Hahm K-S et al. (2014) A helix-PXXP-helix peptide with antibacterial activity without cytotoxicity against MDRPA-infected mice. Biomaterials 35, 1025-1039.
 
Levay PF, Viljoen M (1995) Lactoferrin: a general review. Haematologica 80, 252-267.
 
Li Y, Liu X, Zhu Y et al. (2013) Bioinformatic prediction of epitopes in the Emy162 antigen of Echinococcus multilocularis. Exp ther Med 6, 335-340.
 
Liberto MC, Marascio N (2022) Special Issue “Chronic HCV Infection: Clinical Advances and Eradication Perspectives”. Multidiscip resp med. pp. 359.
 
Lindahl E, Abraham M, Hess B et al. (2019) GROMACS 2019.4 source code. Zenodo.
 
Mangia A, Albanese AP, Bourliére M et al. (2021) Guidelines Have a Key Role in Driving HCV Elimination by Advocating for Simple HCV Care Pathways. Adv Ther 38, 1397-1403.
 
Manns JM (2011) SDS‐polyacrylamide gel electrophoresis (SDS‐PAGE) of proteins. Current Prot Microbiol 22, A. 3M. 1-A. 3M. 13.
 
Miao M, Jing X, De Clercq E et al. (2020) Danoprevir for the treatment of hepatitis C virus infection: Design, development, and place in therapy. Drug Des Dev Ther 14, 2759.
 
Pirkhezranian Z, Tahmoorespur M, Daura X et al. (2020a) Interaction of camel Lactoferrin derived peptides with DNA: a molecular dynamics study. BMC Genomics 21, 1-14.
 
Pirkhezranian Z, Tahmoorespur M, Monhemi H et al. (2020b) Computational peptide engineering approach for selection the best engendered camel Lactoferrin-derive peptide with potency to interact with DNA. Int J Pept Res Ther 26, 2203-2212.
 
Redwan EM, El-Fakharany EM, Uversky VN et al. (2014) Screening the anti infectivity potentials of native N-and C-lobes derived from the camel lactoferrin against hepatitis C virus. BMC Complem Altern M 14, 1-16.
 
Redwan ERM, Tabll A (2007) Camel lactoferrin markedly inhibits hepatitis C virus genotype 4 infection of human peripheral blood leukocytes. J Immunoass Immunoch 28, 267-277.
 
Saleh NA, Elshemey WM (2017) Structure-based drug design of novel peptidomimetic cellulose derivatives as HCV-NS3 protease inhibitors. Life Sci 187, 58-63.
 
Schwede T, Kopp J, Guex N et al. (2003) SWISS-MODEL: an automated protein homology-modeling server. Nucleic Acids Res 31, 3381-3385.
 
Shen M, Zhou S, Li Y et al. (2013) Discovery and optimization of triazine derivatives as ROCK1 inhibitors: molecular docking, molecular dynamics simulations and free energy calculations. Mol Biosyst 9, 361-374.
 
Shiffman ML, Long AG, James A et al. (2014) My treatment approach to chronic hepatitis C virus. In: Mayo Clinic Proceedings. Elsevier pp. 934-942.
 
Simmonds P, Bukh J, Combet C et al. (2005) Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42, 962-973.
 
Sinha M, Kaushik S, Kaur P et al. (2013) Antimicrobial lactoferrin peptides: the hidden players in the protective function of a multifunctional protein. Int J Pept 2013.
 
Smith DB, Pathirana S, Davidson F et al. (1997) The origin of hepatitis C virus genotypes. J Gen Virol 78, 321-328.
 
Solomon S, Wagner-Cardoso S, Smeaton L et al. (2021) A simple and safe approach to HCV treatment: findings from the A5360 (MINMON) trial. Top Med 38-38.
 
Tahmoorespur M, Azghandi M, Javadmanesh A et al. (2020) A novel chimeric anti-HCV peptide derived from camel lactoferrin and molecular level insight on its interaction with E2. Int J Pept Res Ther 26, 1593-1605.
 
Tanhaiean A, Azghandi M, Razmyar J et al. (2018) Recombinant production of a chimeric antimicrobial peptide in E. coli and assessment of its activity against some avian clinically isolated pathogens. Microb Pathogenesis 122, 73-78.
 
Tomita M (1994) The active peptide of lactoferrin. Acta Paediatr Japon 36, 585-591.
 
Ueno H, Sato T, Yamamoto S et al. (2006) Randomized, double‐blind, placebo‐controlled trial of bovine lactoferrin in patients with chronic hepatitis C. Cancer Sci 97, 1105-1110.
 
van der Kraan MI, Groenink J, Nazmi K et al. (2004) Lactoferrampin: a novel antimicrobial peptide in the N1-domain of bovine lactoferrin. Peptides 25, 177-183.
 
van der Kraan MI, Nazmi K, Teeken A et al. (2005) Lactoferrampin, an antimicrobial peptide of bovine lactoferrin, exerts its candidacidal activity by a cluster of positively charged residues at the C-terminus in combination with a helix-facilitating N-terminal part. Biol Chem 137-142.
 
Van Der Spoel D, Lindahl E, Hess B et al. (2005) GROMACS: fast, flexible, and free.  26, 1701-1718.
 
Wang Z, Wang G (2004) APD: the antimicrobial peptide database. Nucleic Acids Res 32, D590-D592.
 
Watashi K, Shimotohno K (2007) Chemical genetics approach to hepatitis C virus replication: cyclophilin as a target for anti‐hepatitis C virus strategy. Rev Med Virol 17, 245-252.
 
Yadav O, Negi S (2020) Molecular dynamics simulations to see the effect of temperature and pressure change on the dynamics of protein. Int J Innov Phis 1, 24-29.
 
Yamauchi K, Tomita M, Giehl T et al. (1993) Antibacterial activity of lactoferrin and a pepsin-derived lactoferrin peptide fragment. Infect Immun 61, 719-728.
 
Yun Z, Lara C, Johansson B et al. (1996) Discrepancy of hepatitis C virus genotypes as determined by phylogenetic analysis of partial NS5 and core sequences. J Med Virol 49, 155-160.
Agricultural Biotechnology Journal
Volume 14, Issue 2
May 2022
Pages 21-44

Files

Share

How to cite

Statistics